LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.08 2.86

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.08

Max

1.09

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Aktsiakasum	-0.27
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+380.91% upside

Turustatistika
By TradingEconomics
Turukapital	-1.1M 125M
Eelmine avamishind	-1.78
Eelmine sulgemishind	1.08

Uudiste sentiment

By Acuity

91%

10 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. nov 2025, 17:44 UTC

Tulu

Suurimad hinnamuutused turgudel

Deere Warns of Tough Year Ahead as Earnings, Sales Fall -- Update

27. nov 2025, 00:00 UTC

Market Talk

Rio Tinto's Coming Investor Briefing Seen Focused on Costs, Lithium, Asset Sales -- Market Talk

26. nov 2025, 23:47 UTC

Market Talk

Nikkei May Rise as Fears About Potential AI Bubble Ease -- Market Talk

26. nov 2025, 23:28 UTC

Market Talk

Mortgage Refinancing in New Zealand Will Spur Recovery -- Market Talk

26. nov 2025, 23:21 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26. nov 2025, 23:21 UTC

Market Talk

RBNZ Rate Cuts Finally Getting Traction With Consumers -- Market Talk

26. nov 2025, 23:02 UTC

Market Talk

Steelmaking Coal Price Signal Knocked by China Import Shift -- Market Talk

26. nov 2025, 21:38 UTC

Tulu

These Stocks Moved the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. nov 2025, 21:25 UTC

Tulu

Li Auto Posts Surprise Loss, Stock Rises. What's Next for Its Diving EV Sales. -- Barrons.com

26. nov 2025, 21:17 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Co Announces Closing of $2B Senior Notes Offering

26. nov 2025, 21:16 UTC

Tulu

Deere Beat Earnings Estimates. Why the Stock Is Falling. -- Barrons.com

26. nov 2025, 21:09 UTC

Tulu

Roblox Isn't Playing Games. Why the Stock Could -2-

26. nov 2025, 21:09 UTC

Tulu

Roblox Isn't Playing Games. Why the Stock Could Jump 50%. -- Barrons.com

26. nov 2025, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Charter Communications Stock Is a Disaster. The Answer Could Be a 10% Dividend. -- Barrons.com

26. nov 2025, 20:25 UTC

Omandamised, ülevõtmised, äriostud

Charter Communications Stock Is a Disaster. The Answer Could Be a 10% Dividend. -- Barrons.com

26. nov 2025, 20:15 UTC

Tulu

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. nov 2025, 20:08 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

26. nov 2025, 20:06 UTC

Market Talk

U.S. Natural Gas Settles Higher Ahead of Holiday -- Market Talk

26. nov 2025, 19:30 UTC

Tulu

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. nov 2025, 19:21 UTC

Omandamised, ülevõtmised, äriostud

Teck Resources: ISS and Glass Lewis Recommend Teck Hldrs Vote for Anglo American Deal

26. nov 2025, 18:43 UTC

Market Talk

U.S. Natural Gas Storage Down for Second Straight Week -- Market Talk

26. nov 2025, 18:41 UTC

Market Talk

U.S. Oil Rig Count Falls By 12 to 407 -- Market Talk

26. nov 2025, 18:19 UTC

Tulu

Workday Beat Earnings Estimates. The Stock Is Down 10% Anyway. -- Barrons.com

26. nov 2025, 17:51 UTC

Tulu

Deere Forecasts Higher Tariff Costs, Less Profit in 2026 -- WSJ

26. nov 2025, 17:50 UTC

Tulu

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. nov 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

26. nov 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26. nov 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

26. nov 2025, 17:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Blue Owl Is Having a Rough Year. Its Co-CEO Says -2-

26. nov 2025, 17:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Blue Owl Is Having a Rough Year. Its Co-CEO Says Investors' Fears Are 'Ungrounded.' -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

380.91% tõus

12 kuu keskmine prognoos

Keskmine 5.29 USD 380.91%

Kõrge 8 USD

Madal 2 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

10 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.